Prof. Xiaodong Zhu 朱晓东
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of gastrointestinal malignancies, including gastric cancer, colorectal cancer, stromal tumors, and neuroendocrine tumors, using chemotherapy, targeted therapy, and immunotherapy.
Dr. Zhu received a medical doctorate from Fudan University in 2003 and joined the Department of Medical Oncology at Fudan University Shanghai Cancer Center. Clinical focus includes comprehensive treatment of solid tumors, especially digestive tract cancers. Research interests include drug resistance mechanisms and efficacy prediction in digestive tract tumors.
Professional roles
- Member, Tumor Targeted Therapy Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Hereditary Digestive Tract Tumor Professional Committee, Shanghai Anti-Cancer Association
- Vice Chair, Colorectal Cancer Professional Committee, Oncology Branch, Shanghai Social Medical Institutions Association
- Editorial Board Member, Annals of Oncology Excerpts China Edition (GI Tumors)
Name order: in Chinese the family name comes first (Zhu Xiaodong). Papers usually list the name as Xiaodong Zhu or Zhu X.
Selected publications
85 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- Redox Biol, 2026 (senior author): Cancer-associated fibroblast-derived POSTN as a metabolic "switch" shapes lipid-stressed macrophage polarization in gastric cancer. PubMed 42731290
- Sci Rep, 2024 (senior author): Identifying an immunosenescence-associated gene signature in gastric cancer by integrating bulk and single-cell sequencing data. PubMed 39048596
- Biochim Biophys Acta Mol Basis Dis, 2024 (senior author): Single cell and bulk RNA sequencing identifies tumor microenvironment subtypes and chemoresistance-related IGF1(+) cancer-associated fibroblast in gastric cancer. PubMed 38484940
- Front Endocrinol (Lausanne), 2023 (senior author): Multi-dimension metabolic prognostic model for gastric cancer. PubMed 38144563
- Cancer Commun (Lond), 2022 (first author): XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). PubMed 35212487
- Front Oncol, 2021 (senior author): Identification of a Four-Gene-Based SERM Signature for Prognostic and Drug Sensitivity Prediction in Gastric Cancer. PubMed 35096599
- BMC Cancer, 2021 (senior author): The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy. PubMed 34740324
- Acta Biochim Biophys Sin (Shanghai), 2021 (senior author): Combined chemotherapy of platinum and fluorouracil promotes T cell-mediated antitumor immunity. PubMed 33201175
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion